<DOC>
	<DOC>NCT00956761</DOC>
	<brief_summary>This is a trial for annual registration of the updated seasonal influenza vaccine formulation.</brief_summary>
	<brief_title>Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1, Seasonal Influenza Vaccine, Formulation 2009-2010</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>MF59 oil emulsion</mesh_term>
	<criteria>Key Subjects of 65 years of age or older Mentally competent Willing and able to give written informed consent prior to study entry Able to comply with all the study requirements In general good health Key Any serious chronic or acute disease disease History of any anaphylactic reaction and/or serious allergic reaction following a vaccination A proven hypersensitivity to any component of the study vaccine Known or suspected (or have a high risk of developing) impairment/alteration of immune function (excluding that normally associated with advanced age) Bleeding diathesis or conditions associated with prolonged bleeding time that in the investigator's opinion would interfere with the safety of the subject Within the past 12 months, participants had received more than one injection of influenza vaccine Within the past 6 months, participants had laboratory confirmed influenza disease or received influenza vaccine</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Influenza vaccine</keyword>
</DOC>